Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer

Key Points

• To explore the role of genomic profiling in guiding treatment decisions for metastatic castration-resistant prostate cancer.
• Comprehensive genomic profiling (CGP) was performed on patients with metastatic castration-resistant prostate cancer (CRPC).
• The study assessed the identification of specific genomic alterations and their correlation with therapy outcomes.
• Data analysis focused on the prevalence of BRCA pathogenic variants, MSI-high, and TMB-high status.
• 20% of patients with metastatic CRPC had BRCA pathogenic variants, MSI-high, or TMB-high.
• Only a subset of identified patients received matched therapeutic interventions.
• The findings support earlier implementation of CGP in treatment planning.